Literature DB >> 31688526

Long-Term Outcomes of Robotic-Assisted Laparoscopic Sacrocolpopexy Using Lightweight Y-Mesh.

Patrick J Culligan1, Christa Lewis2, Jennifer Priestley3, Nyarai Mushonga2.   

Abstract

OBJECTIVE: The objective of this study was to describe anatomic and symptomatic outcomes at 5 years or longer after robotic-assisted laparoscopic sacrocolpopexy using very lightweight polypropylene Y-mesh.
METHODS: A prospective analysis of consecutive patients who underwent surgery at a single center between 2007 and 2011 was performed. Patients consented to objective and subjective assessment at 5 years or longer postoperatively. Surgical success was defined as meeting all of the following: (1) no retreatment for pelvic organ prolapse (POP) since surgery, (2) no prolapse beyond the introitus, (3) no apical descent below -5, and (4) no prolapse symptoms reported. Secondary outcome measures included Sandvik Incontinence Severity Index, the PFDI-20, the PFIQ-7, the PISQ-12, and the SSQ-8), rates of dyspareunia, mesh complications, and subjects' need for any surgical or nonsurgical prolapse treatment since their index surgery.
RESULTS: Eighty percent of the potential study group (253/316) presented for examination and subjective assessment at 5 years or longer after their index surgeries.The surgical success rate was 226 (89.3%) of 253 with no apical failures. Only 4.4% (11/253) of the group met both objective and subjective failure criteria. Sixteen patients were classified as surgical failure owing to subjective criteria alone despite having no significant objective prolapse on examination. Ten patients (4%) elected to undergo subsequent POP repair. These operations consisted of 5 native tissue anterior repairs and 5 native tissue posterior repairs. In addition, 1 patient elected to use a pessary for recurrent anterior POP. The remaining 16 patients who experienced surgical failure elected no further prolapse treatment.
CONCLUSIONS: Robotic-assisted laparoscopic sacrocolpopexy using very lightweight mesh provided excellent long-term results with no mesh-related complications.

Entities:  

Mesh:

Year:  2020        PMID: 31688526     DOI: 10.1097/SPV.0000000000000788

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   2.091


  6 in total

1.  Assessing pelvic organ prolapse recurrence after minimally invasive sacrocolpopexy: does mesh weight matter?

Authors:  Lauren E Giugale; Molly M Hansbarger; Amy L Askew; Anthony G Visco; Jonathan P Shepherd; Megan S Bradley
Journal:  Int Urogynecol J       Date:  2021-02-26       Impact factor: 2.894

2.  Mesh complications after total vs supracervical laparoscopic hysterectomy at time of minimally invasive sacrocolpopexy.

Authors:  Deepanjana Das; Allison Carroll; Margaret Mueller; Kimberly Kenton; Christina Lewicky-Gaupp; Sarah Collins; Julia Geynisman-Tan; C Emi Bretschneider
Journal:  Int Urogynecol J       Date:  2022-06-06       Impact factor: 1.932

3.  Contemporary Use and Techniques of Laparoscopic Sacrocolpopexy With or Without Robotic Assistance for Pelvic Organ Prolapse.

Authors:  Patrick J Culligan; Cristina M Saiz; Peter L Rosenblatt
Journal:  Obstet Gynecol       Date:  2022-04-05       Impact factor: 7.623

Review 4.  Mesh exposure following minimally invasive sacrocolpopexy: a narrative review.

Authors:  Stephanie Deblaere; Jan Hauspy; Karen Hansen
Journal:  Int Urogynecol J       Date:  2022-02-28       Impact factor: 1.932

5.  Patient surgical satisfaction after da Vinci® single-port and multi-port robotic-assisted radical prostatectomy: propensity score-matched analysis.

Authors:  Jonathan Noël; Marcio Covas Moschovas; Marco Sandri; Seetharam Bhat; Travis Rogers; Sunil Reddy; Cathy Corder; Vipul Patel
Journal:  J Robot Surg       Date:  2021-06-18

6.  Robot-assisted sacrocolpopexy: not only for vaginal vault suspension? An observational cohort study.

Authors:  Femke van Zanten; Egbert Lenters; Ivo A M J Broeders; Steven E Schraffordt Koops
Journal:  Int Urogynecol J       Date:  2021-06-23       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.